Since its lows in mid-October, biotech stocks have sparkled, particularly the Big four – Amgen (AMGN), Biogen Idec (BIIB), Celgene (CELG), and Gilead (GILD) – which have demonstrated sustainable growth pathways. With the market’s renewed volatility in recent days, they have pulled back some, which only made them much more reasonably priced.But the more attractive buys in the sector, say […]
View gallery.Many biotech stocks have been breaking out over the past two months.Newlink Genetics Corp and Incyte Corporation both skyrocketed in October.After that, stocks of Ariad Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. both had nice, quick pops last month.Then there was Kite Pharma Inc’s huge jump earlier this month.
So, Who’s Next?
The Company: Sangamo Biosciences, Inc.Ticker Symbol: (NASDAQ: SGMO)Sector: HealthcareIndustry: BiotechnologySangamo focuses on the research, development and […]
NEW YORKThe stock market has gotten a bit more finicky over the past week, and that begs the question of whether or not investors could be in for a rocky start to 2015.If so, investors should be putting together their plans for handling a market drop now, rather than risk reacting poorly when the tape is tumbling. With that in […]
Source:
Patently Biotech’s Top Articles of 2014
See which stocks are being affected by Social Media
[…]
Read more:
Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
[…]
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked ;the Twittersphere for their favorite drug stocks going into next year.
What’s your favorite stock for 2015 in biotech or Pharma?
– Mark Schoenebaum (@MarkSchoenebaum) December 12, 2014What was the top pick? A 21-way tie for first place. All 21 companies got a single vote.I kid you not. As I’m writing […]
To say that biotech stocks have performed well as a group over the last two years is an understatement; they have absolutely crushed the broader markets. For example, the iShares Nasdaq Biotech Index has more than tripled the performance of the S&P 500 , and more than doubled the NASDAQ Composite , since 2012.This sustained move upward, though, has repeatedly […]
Source: MercK & Co.,Just when it looked as though the stock market couldn’t possibly finish the year higher, after its swoon in October, it proved the naysayers wrong. As of this writing, the S&P 500 has risen by 11% for the year, a tad bit higher than the stock markets’ historic annual return.But if you think that’s a solid return, […]
Source: Flickr user Allan Ajifo .Picking winning stocks isn’t easy, especially in biotechnology where the ebb and flow of news tied to drug trials can cause breathtaking share price pops and drops. Although that means that biotech stocks can be risky, the right knowledge can help improve the odds of finding the right investment. We asked three Motley Fool analysts […]
View gallery.A recent report by Morgan Stanley predicts a greater than 40 percent growth in the Hepatitis C (HCV) market in 2015. Projections indicate that the HCV market could be worth $15 billion in upcoming years, with two-thirds of treatment occurring in the United States.
HCV Forerunners Gilead And AbbVie
Morgan Stanley projects that Gilead Sciences, Inc.’s (NASDAQ: GILD) Harvoni and Sovaldi […]
